戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                     We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 cent
2                                               In a phase 2, randomized, double-blind, placebo-controlled trial, we random
3                 DESIGN, SETTING, AND PARTICIPANTS: Phase 3, randomized, double-blind, placebo-controlled trial conducted
4                                     We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm
5                     EXPLORER-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investi
6                                            In this phase 3, randomized, double-blind, placebo-controlled trial, we assign
7                                                           A randomized, double-blind, placebo-controlled trial was used.
8                                              We conducted a randomized, double-blind, placebo-controlled trial across the
9                                              We conducted a randomized, double-blind, placebo-controlled trial in treatme
10                                              We conducted a randomized, double-blind, placebo-controlled trial of amitrip
11                                To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglit
12                                              We conducted a randomized, double-blind, placebo-controlled trial to assess
13                                              We conducted a randomized, double-blind, placebo-controlled trial to investi
14                                        We hence conducted a randomized, double-blind, placebo-controlled trial with newly
15 ore and after treatment samples from subjects enrolled in a randomized, double-blind, placebo-controlled trial of Cat-PAD
16                                                        In a randomized, double-blind, placebo-controlled trial of tenofov
17  confirmed loiasis and &5000 mf/mL blood were enrolled in a randomized, double-blind, placebo-controlled trial of the hum
18                                                  Methods: A randomized, double-blind, placebo-controlled trial was conduc
19                        DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted
20                                              We performed a randomized, double-blind, placebo-controlled trial involving
21                                              We performed a randomized, double-blind, placebo-controlled trial testing th
22   We yoked anatomical brain magnetic resonance imaging to a randomized, double-blind, placebo-controlled trial (RCT) of a
23                                      ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled trial comparing
24                                      METHODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing
25                                                  This was a randomized, double-blind, placebo-controlled trial in which p
26                                               FOURIER was a randomized, double-blind, placebo-controlled trial involving
27 Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving
28                 The Vitamin D Assessment (ViDA) study was a randomized, double-blind, placebo-controlled trial of vitamin
29                                                  This was a randomized, double-blind, placebo-controlled trial with 634 s
30      We conducted a mosquito feeding study, nested within a randomized, double-blind, placebo-controlled trial of 141 adu
31                                   This was a single-centre, randomized, double-blind, placebo-controlled trial.
32 outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving
33                                                A factorial, randomized, double-blind, placebo-controlled trial was conduc
34 ory bacterium-like particle (BLP).Methods: In this phase I, randomized, double-blind, placebo-controlled trial, 48 health
35            The authors conducted an investigator-initiated, randomized, double-blind, placebo-controlled trial involving
36                                    We performed a 12-month, randomized, double-blind, placebo-controlled trial of pomegra
37                                  We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR
38                                     This was a multicenter, randomized, double-blind, placebo-controlled trial involving
39                                 We performed a multicenter, randomized, double-blind, placebo-controlled trial involving
40                                 We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluat
41                                 We performed a multicenter, randomized, double-blind, placebo-controlled trial with Alt a
42 t of patients who participated in a phase III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.
43 rd care.Methods: In an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial, patients
44                           In this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT rec
45                                           This multicenter, randomized, double-blind, placebo-controlled trial was perfor
46                                                        This randomized, double-blind, placebo-controlled trial assessed t
47                                                        This randomized, double-blind, placebo-controlled trial included p
48                                     We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluat
49                                        METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included p
50 ith schizotypal personality disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfac